Clinical Considerations of Amikacin Pharmacotherapy in Adults—A Narrative Review with Focus on Safety and TDM
Daniel Orzechowski, Aleksandra Mroczkowska, Adrian Bryła, Anna Rapacz · 2026
Read Clinical Considerations of Amikacin Pharmacotherapy in Adults—A Narrative Review with Focus on Safety and TDM by Daniel Orzechowski, Aleksandra Mroczkowska, Adrian Bryła, Anna Rapacz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13295988.txt.
Description
Daniel Orzechowski and colleagues review how to use amikacin safely in adults, in a 2026 narrative review. The antibiotic still kills most Gram-negative bacteria, among them drug-proof strains, and rarely triggers a gut infection that haunts other drugs. Its use is capped by harm to kidneys and ears. The team drew on fifty-six works to weigh dosing, drug level checks, and safety.
How best to watch drug levels stays unsettled, and guide targets vary widely on thin proof. Lower trough levels tied to less kidney harm, yet no firm safe line emerged. Illness severity, kidney swings, and partner drugs such as vancomycin all shift the risk, and ear harm stays a live worry. The authors call for dosing shaped to each patient and for trials that test watch plans head to head.
Catalog record
| CREATOR | Daniel Orzechowski, Aleksandra Mroczkowska, Adrian Bryła, Anna Rapacz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |